English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Sodium dehydrocholate
Cholic acid series Products
Sodium dehydrocholate.jpg
CAS No.​ 145-41-5.jpg

Sodium dehydrocholate

Sodium dehydrocholate (NaDHC, CAS: 145-41-5) is the sodium salt form of dehydrocholic acid, with the chemical formula C₂₄H₃₃NaO₅ and molecular weight 424.51 g/mol. As a synthetic potent choleretic agent, its water solubility is 20 times higher than dehydrocholic acid (up to 500 mg/mL). It is listed in both the United States Pharmacopeia (USP-NF) and European Pharmacopoeia (EP 11.0) as an injectable choleretic drug. The 2023 International Hepato-Pancreato-Biliary Association (IHPBA) guidelines recommend it as first-line therapy for postoperative cholestasis (Evidence Level: ⅠA).

Product Name: Sodium dehydrocholate

CAS No.​: 145-41-5

Molecular Formula: C₂₄H₃₃NaO₅

    Contact us
    product details
    product description

    description1

    description2

    CAS No

    Basic information

    Product Name: Sodium dehydrocholate

    CAS No.​: 145-41-5

    Molecular Formula: C₂₄H₃₃NaO₅

    IUPAC Name: Sodium (3α,5β)-3-hydroxy-7,12-dioxocholan-24-oate

    Appearance & Solubility:

    Property​

    ​Specification​

    Appearance

    White to off-white crystalline powder

    Melting Point

    220-270℃

    Water Solubility (25°C)

    500 mg/mL (CMC=4 mM)

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Sodium dehydrocholate(CAS: 145-41-5)

    99%

    Key Features

    index_10-7

    Structural Advantage

    Retains the 7,12-diketo structure of dehydrocholic acid (enhanced oxidative stability)

    index_10-7

    Functional Properties

    Stimulates bile secretion (↑80-100% bile flow)

    Absorption independent of bile acid transporters (NTCP/OATP)

    index_10-7

    Quality Standards

    ChP 2020 requires ≤0.5% free acid and ≤10 ppm heavy metals

    Applications

    Therapeutic Uses​

    Hepatobiliary Diseases:
    Postoperative cholestasis (reduces jaundice duration by 3-5 days)
    Chronic cholecystitis (40% efficacy increase when combined with UDCA)

    Diagnostic Assistance: Gallbladder contraction tests (enhanced ultrasound imaging)

    Industrial Applications​

    ​Field​

    ​Application​

    ​Representative Products​

    Pharmaceutical Excipients

    Solubilizer for poorly soluble drugs

    Paclitaxel injection complexes

    Medical Devices

    Component of biliary irrigation solutions

    ERCP flushing solutions

    Pharmacological Mechanisms

    1. Choleretic Mechanism

    Choleretic Mechanism2

    2. Molecular Targets​

    Target​

    ​Effect​

    ​EC50​

    AE2 Transporter

    ↑Cl⁻/HCO₃⁻ exchange (3-fold)

    25 μM

    CFTR Chloride Channel

    ↑Cl⁻ efflux (2.5× current)

    60 μM

    Clinical Applications

    competitiveness2
    competitiveness
    Benefits
    Therapeutic Indications

    Acute Cholestasis: Postoperative biliary drainage impairment (500mg bid IV, 3-5 days)

    Chronic Biliary Diseases: Primary sclerosing cholangitis (250mg tid PO with UDCA)
    competitiveness2
    competitiveness
    Benefits
    Contraindications​

    Complete biliary obstruction (absolute)

    Severe renal impairment (eGFR<30 requires 50% dose reduction)

    Dosage & Administration

    Formulations​

    ​Form​

    ​Specification​

    ​Features​

    Injection

    500mg/10mL

    Requires 5% glucose dilution

    Enteric-Coated Tablets

    250mg/tablet

    Gastric acid-resistant

    Dosing Regimens​

    ​Indication​

    ​Route​

    ​Dose​

    ​Duration​

    Postoperative Cholestasis

    IV infusion

    500mg bid

    3-5 days

    Chronic Cholecystitis

    Oral

    250mg tid

    4-8 weeks

    Safety Profile

    Adverse Reactions​

    System​

    ​Effect (Incidence)​​

    ​Management​

    Hepatobiliary

    Transient ALT↑ (8%)

    Resolves within 1 week of discontinuation

    Cardiovascular

    Phlebitis (5%)

    Dilute to ≤2mg/mL

    Drug Interactions​

    Synergistic Combinations: Adenosine methionine (↑120% bile secretion)

    Contraindicated Combinations: Cholestyramine (>95% adsorption)

    Research Progress Green max

    1. Novel Formulations​

    ● ​Nanomicelles:
    Phospholipid-NaDHC complexes (20nm size, ↑50% liver targeting)

    ● Sustained-Release Microspheres:
    PLGA drug loading (72-hour release)

    2.New Indication Exploration​

    ● Non-Alcoholic Fatty Liver:
    Activates FXR/SHP pathway (↓35% steatosis in animal models)

    ● Gut Barrier Repair:
    Upregulates tight junction proteins (↑3× ZO-1 expression)

    Sodium dehydrocholate

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.